In July of 2015, Deerfield invested in TriNetX, a development stage company based in Cambridge, MA. The company has developed a novel technology solution that can help drug companies and CROs predict the impact of various inclusion and exclusion criteria on the size of eligible patient populations as well as to identify those provider sites that have access to highly specific patient populations.